Drug Trial Radar · NCT01396213
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease
Last checked: Nov 19, 2026Latest source record: Sep 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
342
Actual
Start
Nov 7, 2011
Primary completion
Aug 20, 2013
Study completion Aug 20, 2013
Sponsor
- Lead sponsor
- 9 Meters Biopharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Teva Pharmaceuticals USA
- First posted
- Jul 18, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled Phase 2B study to evaluate the efficacy and safety of Larazotide Acetate in the treatment of patients with celiac disease who have persistent symptoms despite being on a gluten-free diet.
Conditions
- Celiac Disease
Interventions
Larazotide AcetateDrug
gelatin capsule
placeboDrug
gelatin capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the efficacy of larazotide acetate versus placebo for the treatment of celiac disease in adults as an adjunct to a gluten-free dietTime frame: CeD GSRS was completed weekly Baseline through the end of 12-week double-blind treatment period.
Locations
62 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mesa, Arizona
Site not named
Tucson, Arizona
Site not named
Oceanside, California
Site not named
Orange, California
Site not named
San Francisco, California
Site not named
Santa Monica, California
Site not named
Walnut Creek, California
Site not named
Denver, Colorado
Site not named
Boynton Beach, Florida
Site not named
Edgewater, Florida
Site not named
Orlando, Florida
Site not named
Summerfield, Florida
Site not named
Marietta, Georgia
Site not named
Chicago, Illinois
Site not named
Rockford, Illinois
Site not named
West Des Moines, Iowa
Site not named
Wichita, Kansas
Site not named
Lexington, Kentucky
Site not named
Louisville, Kentucky
Site not named
Baltimore, Maryland
Site not named
Hagerstown, Maryland
Site not named
Boston, Massachusetts
Site not named
Chesterfield, Michigan
Site not named
Wyoming, Michigan
Site not named
Duluth, Minnesota
Site not named
Rochester, Minnesota
Site not named
Jackson, Mississippi
Site not named
St Louis, Missouri
Site not named
Missoula, Montana
Site not named
Las Vegas, Nevada
Site not named
Marlton, New Jersey
Site not named
Lake Success, New York
Site not named
New York, New York
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
Cary, North Carolina
Site not named
Salisbury, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Cleveland, Ohio
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.